Winner, winner

10 most promising Texas startups revealed at inaugural Houston summit

Station Houston CEO Gabriella Rowe and Rice Alliance Managing Partner Brad Burke named 10 startups to watch. Photo by Natalie Harms

Texas is booming with digital startups, and Station Houston and the Rice Alliance for Technology and Entrepreneurship hosted a meeting of the minds to discuss the digital revolution at the inaugural Texas Digital Summit at Rice University on December 6.

Thirty-nine companies presented throughout the day; among the group were 26 from the Houston area. At the conclusion of the day, Gabriella Rowe, CEO of Station Houston, and Brad Burke, managing director of the Rice Alliance, announced 10 "most promising companies" that stood out to a group of investors who attended the event.

All 10 selected were Texas-based, with eight from the Houston area. Here's who the venture capitalists and investors picked for the prize.

Houston-based SafePass

Photo via safepassglobal.com

SafePass pictures a world where visitors on school or corporate campuses can be tracked. The company's technology upends the standard paper or sticker pass you get from the front office, and provides a reusable, trackable device for visitors.

"Our tracking algorithm interacts with already existing WiFi technology — so, the routers that are already at that facility," says Ronald Huff, managing director of SafePass. "We leverage that to get that real-time tracking information."

Houston-based ScribeRule

Getty Images

ScribeRule operates under the assumption that your company's data has already been breached. The software protects data from both internal and external threats so that companies don't have to worry about any type of threat. The technology is scalable and easy to use.

"The problem is very simple," says Chris Melson, president and COO. "Only allow people who are authorized to see your data, see the data. And that's the problem we've solved."

"It's very difficult to protect data in a collaborative environment."

Houston-based Sensoleak

Photo via sensoleak.com

Sensoleak is making it easier for monitors in the oil and gas industry to be alerted about leaks. Using artificial intelligence, machine learning, and internet of things combined into a software, the company is providing a revolutionary solution for a longstanding problem.

"The problem right now is there is a lot of false alarms," says Shoshi Kaganovsky, founder and CEO, "and if there is a leak, it has to leak a lot before it is caught."

The company recently opened a new round of funding.

Sugar Land-based Commtrex

Photo via commtrex.com

The only open, electronic marketplace for rail shippers and asset providers is right in Houston's backyard of Sugar Land. Commtrex makes communications and connections between these transportation entities more efficient and better executed.

"Commtrex's asset management tools and market data is based on real transactions, and benefits our member companies with engagement efficiencies and financial insights," reads the website.

Houston-based Zenus

Photo via zenus-biometrics.com

Let's face it, face recognition is the future of identification, and Zenus has an award-winning technology to move the needle. Utilizing face recognition doesn't need to compromise privacy.

"We are a leading provider of face recognition software," reads the website. "Our cloud-based service can search a database of faces within a blink of an eye and it can be seamlessly integrated into any application."

Houston-based 3GiG

Photo via 3-gig.com

3GiG is a one-stop shop software company for the "oval office" needs of oil and gas companies. Energy leaders can use the services to manage projects, prospects, and more. President and CEO Kandy Lukats compares her company's services to the trending meal kits — like Blue Apron or Hello Fresh —Americans have been crazy about — all the ingredients sent right to your door.

"We believe we've found the niche between the freezer section and doing it yourself," she says.

Austin-based Towny

Photo via towny.com

This Austin company is making it more appealing to shop local. Towny looks to work in cities with under a million residents. The tool is for small, consumer-focused businesses to market their store to consumers. The small business owners pay a flat monthly rate to utilize digital marketing tools from the convenience of their phones.

Towny is already in five towns with 500 clients, says CEO Nathan Baumeister. In January, the company's monthly revenue was $17,000, but for the last two months, the tool has raked in $90,000 monthly.

"We've built a branding, mobile-first platform, where we've taken all these technologies and tactics and put it together in one package at the affordable price of $199 per month," he says.

Dallas-based CommandHound

Photo via commandhound.com

CommandHound is a B2B software that tracks employee tasks and responsibilities. It reminds users on assigned duties and keeps a record of work outcomes for later performance reviews.

"Our ultimate solution is to turn every organization into a high-performance organization through accountability," says Rene Larrave, chairman and CEO. "It's a checklist on steroids."

Houston-based SecurityGate

Photo via securitygate.io

SecurityGate is disrupting the cyber compliance and the cyber regulation market by providing cyber risk assessments at a faster rate than a human auditor could. The software analyzes data, identifies potential cyber security risks, and communicates with the company how to address the threats.

"No matter what industry vertical you're in, every single supply chain out there is worries about supply chain cyber security," says CEO Ted Gutierrez. "And the problem with that, is everyone is doing it manually."

Houston-based DeepCast.ai

Photo via deepcast.ai

Using artificial intelligence and physics, DeepCast.ai can automate operations for industrial companies.

"We simply integrate with system solutions, try to clean and facilitate the data using AI models important to the oil and gas industry," says Arturo Klie, chief technology officer and senior software engineer. "Once the data is clean, we apply our business-informed AI models to solve and provide forecasting real time and analytics.

Trending News

 
 

Promoted

Emerson Perin of the Texas Heart Institute, recently published the largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America. Photo via texasheart.org

Emerson Perin’s end goal isn’t to treat heart failure. The medical director of The Texas Heart Institute says that he has his sights set firmly on curing the malady altogether. And, with the power of innovation and a strong team, the Houston-based cardiologist has a good chance of meeting his objective.

Perin first came to THI for fellowship training in 1988, following his residency in Miami and medical school in his birthplace of Brazil.

“This is a very special place,” the physician and researcher, whose titles also include director for THI’s Center for Clinical Research and vice president for medical affairs, tells InnovationMap. “It has a worldwide-reaching reputation. I’ve always liked research and this is a great place in terms of innovation and practicing high-level cardiology.”

For decades, Perin has followed in THI founder Denton Cooley’s footsteps with world-changing research. In 2001, the founding medical director of THI’s Stem Cell Center was the first person to inject stem cells into a failing human heart. It led to a trial of 17 patients that year.

“A couple of the patients did remarkably well — more than you could ever expect. These guys who couldn’t’ walk across the room pretty much were jogging on the beach. That gave me the initial insight that this works,” Perin recalls.

What exactly is heart failure? The term refers to the condition of a heart that can’t pump enough blood to sustainably power the body through oxygenation of the tissues from blood flow. It may sound like a death sentence, but with appropriate care, it can usually be managed with medicines and if worsening occurs, devices and, ultimately, heart transplantation.

And Perin is proving that there’s a lot of life ahead for heart failure patients. Earlier this year, he published another groundbreaking clinical trial, DREAM-HF. The largest clinical trial of cell therapy for patients with chronic heart failure to-date included 580 patients at 52 sites throughout North America.

With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.

“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.

But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.

These are blockbuster numbers, and big news for patients dealing with heart failure. What it means is that the cells addressed a different aspect of heart failure that until now had been left untreated which was the inflammation — how heart failure starts and what keeps it going.

So what’s next? Going to the FDA.

“They said, ‘We can’t approve it with one trial, but we’ll approve it with two,’” says Perin.

This time, his primary endpoint will be tailored to suit the positive outcome he knows he’ll be able achieve. This next round will begin in 2024.

Once the FDA approves a new catheter system for injecting the heart with stem cells and genes, the team will proceed with new studies. Gene therapy will be another frontier for Perin — and patients with heart failure.

“I think the combination of cells and genes is even more powerful,” he says. “That will help save lives in a completely new way and do away with heart failure.”

Perin's work is just one piece of the puzzle, and Dr. Joseph Rogers, who was appointed president and CEO of THI in 2021, is leading the organization's initiative in several ways. THI, recently buoyed by a $32 million donation from a patient — the largest charitable donation in its history — is exploring several innovative therapeutics, devices, and treatments.

THI recently received a two-year, $1.14 million grant from The National Heart, Lung, and Blood Institute to develop a novel, first-in-class drug to treat the cardiovascular disease that arises from atherosclerosis. Another THI innovator, Camila Hochman-Mendez — along with her research team — is studying the effects of regenerative medicine on hearts.

Trending News

 
 

Promoted